---
title: "XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279618198.md"
description: "XOMA Royalty Corporation (NASDAQ: XOMA) shares rose 5.70% to $28.54 after reporting Q4 earnings of 26 cents per share, surpassing the expected loss of 15 cents. Revenue reached $13.75 million, exceeding the $11.04 million estimate. The company repurchased 648,048 shares for $16 million and reported cash equivalents of $133.7 million as of Dec. 31, 2025. CEO Owen Hughes highlighted upcoming catalysts with 14 programs in registrational studies and anticipated regulatory updates and clinical readouts in 2026."
datetime: "2026-03-18T13:51:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279618198.md)
  - [en](https://longbridge.com/en/news/279618198.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279618198.md)
generator: "portal-rs"
---

# XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead

**XOMA Royalty Corporation** (NASDAQ:XOMA) shares are trading higher Wednesday after the company reported fourth-quarter financial results.

-   XOMA Royalty stock is trading at elevated levels today. What’s next for XOMA stock?

## Q4 Earnings

XOMA reported earnings per share of 26 cents, beating the consensus estimate of a 15 cent-loss. In addition, it reported revenue of $13.75 million, beating the consensus estimate of $11.04 million.

The company repurchased and retired 648,048 shares for an aggregate of $16.0 million during 2025.

XOMA reported cash and cash equivalents of $133.7 million as of Dec. 31, 2025, including $50.8 million in restricted cash, compared to $106.4 million at the end of 2024.

"Looking ahead, with 14 programs in registrational studies, we anticipate a number of catalysts over the ensuing years, including several regulatory updates and late-stage clinical readouts in 2026," said CEO **Owen Hughes**.

## XOMA Shares Edge Higher

**XOMA Price Action:** At the time of publication, Xoma shares are trading 5.70% higher at $28.54, according to data from Benzinga Pro.

*This illustration was generated using artificial intelligence via Midjourney.*

### Related Stocks

- [XOMAP.US](https://longbridge.com/en/quote/XOMAP.US.md)
- [XOMA.US](https://longbridge.com/en/quote/XOMA.US.md)
- [XOMAO.US](https://longbridge.com/en/quote/XOMAO.US.md)

## Related News & Research

- [XOMA Royalty Reports Strong 2025 Results and Growth](https://longbridge.com/en/news/279600981.md)
- [District Announces Promising Water Treatment Results from Collaboration with Xoma AB | DMXCF Stock News](https://longbridge.com/en/news/286861678.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)
- [Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales](https://longbridge.com/en/news/296529363.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**